Current Headlines

  1. CRT Pioneer Fund, Cancer Research UK Manchester Partner On Lung Cancer Drugs
    11/26/2014

    The Cancer Research Technology Pioneer Fund (CPF) has partnered with the Cancer Research UK Manchester Institute Drug Discovery Unit on RET inhibitors to treat lung cancer, Cancer Research UK announced in a press release.

  2. Merck And NewLink Join Forces For Ebola Vaccine Lead
    11/26/2014

    Merck announced that it has partnered with NewLink Genetics in an exclusive global license agreement to develop NewLink’s rVSV-EBOV (Ebola) vaccine candidate.

  3. China’s Yabao, MRC Technology Partner On Parkinson’s Therapeutics
    11/26/2014

    Yabao Pharmaceuticals has partnered with MRC Technology to develop therapeutics for Parkinson’s disease.

  4. CHMP Backs Genzyme’s Cerdelga For Gaucher Disease
    11/26/2014

    Sanofi firm Genzyme announced that it has received a positive recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for the approval of Cerdelga (eliglustat) for the treatment of Gaucher disease type 1.

  5. AstraZeneca Expands Maryland Biologics Manufacturing Site For $200M
    11/26/2014

    British drug maker giant AstraZeneca announced its plans to expand its Frederick, Maryland biologics manufacturing center in order to support its maturing pipeline, 50 percent of which is comprised of biologics.

  6. Infection-Fighting Biosimilars Expected To Hit $1.8B By 2023
    11/25/2014

    Decisions Resources Group (DRG) surveyed oncologists from France and Germany to gauge their opinion and preferences toward a wave of biosimilars which are poised to enter the market over the next few years.

  7. Amgen Opens Biologics Manufacturing Facility In Singapore
    11/25/2014

    Amgen has finished construction of its biologics manufacturing facility in Tuas, Singapore.

  8. First Chikungunya Vaccine Succeeds In Phase 1 Study
    11/25/2014

    Vienna-based biotech company, Themis Bioscience, has announced the positive results from a phase 1 clinical study of its prophylactic Chikungunya fever vaccine candidate.

  9. ChemoCentryx Gets FDA Orphan Status For Kidney Disease Drug
    11/25/2014

    Clinical stage biopharmaceutical company ChemoCentryx announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for CCX168 as an investigational treatment for atypical Hemolytic Uremic Syndrome (aHUS).

  10. Bristol-Myers Squibb, Five Prime Partner On Opdivo, FPA008 In Tumors
    11/25/2014

    Bristol-Myers Squibb Company (BMS) and Five Prime Therapeutics have entered into a partnership to investigate a combination of BMS’ Opdivo (nivolumab) and Five Prime’s FPA008 to treat six types of malignant tumors.

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.